FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington	D.C.	20549	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average burden									
l	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Sukhatme Mayukh			Roivant Sciences Ltd. [ ROIV ] (Check all applicable									<i>'</i>						
Sukilatille Mayukii												Director			10% Own			
(Last)	(Fi	rst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)						X	Officer (gives)	e title		Other (spo	ecify		
, ,	,	,	(madio)		09/27/2023								Pres&Chief Investment Officer					
C/O ROIVANT SCIENCES LTD.																		
7TH FLOOR, 50 BROADWAY					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
(Street)			Form filed by More than One Reporting Person															
LONDON	X(	)	SW1H 0DB		Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			2. Transac Date (Month/Da		2A. Deemed Execution Date, if any				ties Acquired (A) or I Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially	Form:		Direct Ir	. Nature of ndirect		
Į (main							(Month/Day/Year)	Code	v	Amount	(A) (D)	or P	rice	Following Reported Transaction(s) (Instr. 3 and 4)		(i) (Instr. 4)		wnership nstr. 4)
Common Shares 09			09/27/2	/2023			M <sup>(1)(2)(3)</sup>		27,79	27,790 A		(1)(2)(3)	3,217,7	750 <sup>(4)</sup>		D		
Common Shares														1,657,698(5)			I E	By LLC
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amo Securities Unde Derivative Secur (Instr. 3 and 4)			rlying	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporte	ive ies cially ing	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title		unt or ber of es			saction(s)		
Capped Value Appreciation Rights	(1)(2)(6)(7)	09/27/2023		М			53,033 <sup>(1)(2)(6)</sup>	(1)(2)(6)		03/31/2026		Common Shares 25,2		\$6.4 <sup>(1)(2)(7)</sup> 2,015,20		263 <sup>(7)</sup>	D	
Capped Value Appreciation	(1)(3)(6)	09/27/2023		М			28,411 <sup>(1)(3)(6)</sup>	(1)(3)(6)		03/31/2026	Common Shares	2,5	41 <sup>(1)(3)</sup>	\$11.5 <sup>(1)(3)</sup>	1,335,	,300	D	

## **Explanation of Responses:**

- . Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at \$12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").
- 2. On September 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 53,033 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 25,249 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023.
- 3. On September 27, 2023, the hurdle price applicable to 28,411 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 2,541 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023.
- 4. Includes an award of restricted stock covering Common Shares that is fully vested.
- 5. Reflects an award of restricted stock covering Common Shares ("RSAs") that is fully vested. The award of RSAs is held by a limited liability company (the "LLC") that is owned by a family trust (the "Trust"). The reporting person has investment control over both the LLC and the Trust. The reporting person disclaims beneficial ownership of the reported securities held by the LLC except to the extent of his pecuniary interest therein.
- 6. This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019.
- 7. In the event the fair market value of a Common Share is less than \$9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs.

By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme

09/29/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.